Stearic Acid

Stearic Acid

SCHEMBL9243538

CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Ca+2].[Ca+2]

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FABP3 P05413 7/20 0.72
▸ CA1 P00915 1/20 0.71
▸ CES2 O00748 4/20 0.67
▸ CES1 P23141 4/20 0.67
▸ FFAR3 O14843 1/20 0.57
▸ HDAC3 O15379 1/20 0.57
▸ HDAC1 Q13547 1/20 0.57
▸ HDAC2 Q92769 1/20 0.57
▸ HDAC8 Q9BY41 1/20 0.57
▸ NFKB1 P19838 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8743307 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Stearic Acid SCHEMBL13836877 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Palmitic Acid SCHEMBL141829 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Myristic Acid SCHEMBL360184 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Undecanoate SCHEMBL11343015 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Heptanoate SCHEMBL588180 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Decanoic Acid SCHEMBL453322 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Stearic Acid SCHEMBL2371 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Arachidic Acid SCHEMBL7629156 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3
Lignoceric Acid SCHEMBL262204 1.00 FABP3 (0.72) FABP3CA1CES2CES1FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103881258-A PVC (Polyvinyl Chloride) building plastic template and manufacturing method thereof SHANDONG JINHUA CONSTRUCTION GROUP CO LTD 2014-06-25 — — CN claimed
US-12570776-B2 Superior C2C3C4 terpolymer based blown film and C2C3C4 terpolymer BOREALIS AG (AT) 2026-03-10 — — US disclosed
US-20240101771-A1 SUPERIOR C2C3C4 TERPOLYMER BASED BLOWN FILM AND C2C3C4 TERPOLYMER BOREALIS AG (AT) 2024-03-28 — — US disclosed
EP-4288468-A1 SUPERIOR C2C3C4 TERPOLYMER BASED BLOWN FILM AND C2C3C4 TERPOLYMER Borealis AG (AT) 2023-12-13 — — EP disclosed
US-11661511-B2 Production method of polyacetal resin composition POLYPLASTICS CO., LTD. (JP) 2023-05-30 — — US disclosed
CN-217666208-U Special air door for sand mixer 合肥仁创铸造材料有限公司 2022-10-28 — — CN disclosed
EP-3449943-B1 A PHARMACEUTICAL COMPOSITION FOR IMPROVING OR PREVENTING PROGRESSION OF CHRONIC KIDNEY DISEASE FRIMLINE PRIVATE LTD (IN) 2022-08-31 — — EP disclosed
US-20220089858-A1 PRODUCTION METHOD OF POLYACETAL RESIN COMPOSITION POLYPLASTICS CO., LTD. (JP) 2022-03-24 — — US disclosed
US-10973782-B2 Pharmaceutical composition for improving or preventing progression of chronic kidney disease FRIMLINE PRIVATE LIMITED (IN) 2021-04-13 — — US disclosed
US-20190070133-A1 PHARMACEUTICAL COMPOSITION FOR IMPROVING OR PREVENTING PROGRESSION OF CHRONIC KIDNEY DISEASE FRIMLINE PRIVATE LIMITED (IN) 2019-03-07 — — US disclosed
CN-106186744-A A kind of novel morning strong foam cement 卓达新材料科技集团威海股份有限公司 2016-12-07 — — CN disclosed
CN-106145760-A A kind of Novel foaming cement additive 卓达新材料科技集团威海股份有限公司 2016-11-23 — — CN disclosed
CN-103881258-B PVC building plastic formwork and preparation method SHANDONG JINHUA CONSTRUCTION GROUP CO., LTD. (CN) 2016-03-23 — — CN disclosed
CN-103881258-B PVC building plastic formwork and preparation method SHANDONG JINHUA CONSTRUCTION GROUP CO., LTD. (CN) 2016-03-23 — — CN disclosed
WO-2015047999-A1 SUSTAINABLE POLY(VINYL HALIDE) MIXTURES FOR THIN-FILM APPLICATIONS POLYONE CORPORATION (US) 2015-04-02 — — WO disclosed
CN-103881258-A PVC (Polyvinyl Chloride) building plastic template and manufacturing method thereof SHANDONG JINHUA CONSTRUCTION GROUP CO LTD 2014-06-25 — — CN disclosed
WO-2014070355-A1 USE OF POLYCAPROLACTONE PLASTICIZERS IN POLY(VINYL CHLORIDE) COMPOUNDS POLYONE CORPORATION (US) 2014-05-08 — — WO disclosed
CN-1564668-A Cushion body and foamed resin particles for filling the same SEKISUI PLASTICS (JP) 2005-01-12 — — CN disclosed
US-5422061-A Dry blending ultra high molecular weight polyethylene powders and additives, injection molding, compressing; friction resistance, wear resistance DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) 1995-06-06 — — US disclosed
US-5232702-A SILICONE PRESSURE SENSITIVE ADHESIVE COMPOSITONS FOR TRANSDERMAL DRUG DELIVERY DEVICES AND RELATED MEDICAL DEVICES DOW CORNING CORPORATION (US) 1993-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570776-B2 Superior C2C3C4 terpolymer based blown film and C2C3C4 terpolymer MCM3, EMC3, ATL3 FABP3 1005/4885CA1 3149/4885CES2 4154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback